Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
We developed new therapeutic drugs that inhibit oligomer formation of polyglutamine disease proteins based on the hypothesis of oligomer toxicity in polyglutamine diseases. Using a disease nematode model, we found a small compound that inhibit oligomer formation of disease proteins and ameliorate motor function of the nematode model. We also developed a novel system using iPad for the quantitative assessment of cerebellar ataxia. In addition, we started a clinical trial to investigate the safety and efficiency of varenicline (Champix), a prescription medication used to treat nicotine addiction, in the treatment of spinocerebellar degenerations.
|